Skip to main content
. 2022 Oct 27;13:986565. doi: 10.3389/fendo.2022.986565

Table 1.

Potential drugs and agents that inhibit NLRP3 inflammasome signaling pathways.

Drugs Complications Natural or Angents Complications
Metformin DCM Melatonin DCM, DPN, AS
Liralutide DCM, DPN, NAFLD H3 relaxin DCM, DR
Exenatide NAFLD, DCM Exendin-4 DCM
Dapagliflozin DCM Nab DN
Saxagliptin DCM miRNA DN, DCM, DR, DPN
Chinese medicine DN, DCM, DPN, DR LncRNA DN, DCM, DPN
MCC950 DR